TMFMassimo

Article

TMFMassimo published an article 6:30 PM

Regeneron and Sanofi: An Unstoppable Biotech Duo?

More positive clinical trial data released today.

Article

TMFMassimo published an article 6:30 PM

What's Behind Medtronic's 5% Pop?

Fourth-quarter results impressed investors today.

Article

TMFMassimo published an article 6:30 PM

Will the FDA Approve Merck's Insomnia Drug?

The advisory committee meeting is this Wednesday, but investors will have to wait until the summer to discover the Food and Drug Administration's decision.

Article

TMFMassimo published an article 6:30 PM

AbbVie's New Crohn's Disease Drug Candidate

Galapagos and AbbVie's experimental Crohn's disease drug GLPG0634 is entering a phase 2 clinical study.

Article

TMFMassimo published an article 7:24 PM

Is Keryx Biopharmaceuticals Burning Too Much Cash?

What is Keryx's burn rate, and how much cash does it have on hand?

Article

TMFMassimo published an article 6:30 PM

AbbVie Investors, Watch This Management Change

What strategy will the company's new chief scientific officer pursue?

Article

TMFMassimo published an article 8:00 AM

The New Generic-Drug Battle Front

One generic pharmaceutical company is determined to chance consumer habits.

Article

TMFMassimo published an article 6:30 PM

3 Most Important Upcoming FDA Decisions of 2013

The Food and Drug Administration will decide on drugs developed by Merck, Antares Pharmaceuticals, and GlaxoSmithKline in the coming months.

Article

TMFMassimo published an article 9:13 PM

Sanofi and Regeneron's Latest Partnership

Late-stage clinical trials begin for this duo's experimental rheumatoid arthritis drug.

Article

TMFMassimo published an article 6:30 PM

What Does This Failure Mean for Eli Lilly Investors?

Eli Lilly announced that it will stop developing cancer drug candidate enzastaurin. What does this mean for its business?

Article

TMFMassimo published an article 12:30 PM

4 Technologies That Can Help Track Weight Loss

Apps and devices that help patients being treated for obesity track their progress.

Article

TMFMassimo published an article 5:58 PM

This Week in Health Care

For the week ended May 10, 2013.

Article

TMFMassimo published an article 2:54 PM

Why NPS Pharmaceuticals Is Up After Earnings

Orphan drugmaker NPS Pharmaceuticals reveals the progress of its Gattex launch.

Article

TMFMassimo published an article 5:00 PM

3 Key Takeaways From Keryx's Earnings Report

What should investors focus on after this biotech's Q1 report?

Article

TMFMassimo published an article 6:30 PM

Is Orexigen Therapeutics Burning Too Much Cash?

What is this biotech's burn rate?

Article

TMFMassimo published an article 9:04 AM

This Week in Health Care

For the week ended May 3, 2013.

Article

TMFMassimo published an article 6:06 PM

Hot Off the Press: Arena Pharmaceuticals’ First Quarter Results

Initial takeaways from Arena's Q1 report.

Article

TMFMassimo published an article 6:30 PM

Is a Pharmaceutical Company the Same as a Biotech?

Have they become the same, or do they have different approaches to drug discovery?

Article

TMFMassimo published an article 6:30 PM

Teva's 3 Biggest Challenges

Teva is one of the largest pharmaceutical companies in the world, but what roadblocks lie ahead?

Article

TMFMassimo published an article 6:30 PM

1 Simple Way to Be a Better Investor

Trying to weight the pros and cons of a potential investment? SWOT away your worries and try this approach.